
Alpha Profiles · Company Profile
ADC Therapeutics SA
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors.
https://registry.alpha.ac/companies/adc-therapeutics-sa
- Entity
- Public listing published
- Primary listing
- NYSE: ADCT
- Verification
- Partially verified
- Last reviewed
- 2026-09-13T04:46:42.426925+00:00
Overview
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients
Source record
Alpha canonical company public projection
Supports Company identity, Published leadership, Entity status boundary
Reviewed 2026-09-13T04:46:42.426925+00:00
